{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-016224","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2023-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.404271+00:00","generated_at":"2026-06-20T08:21:46.838136+00:00","sec_items":["1.01","1.02","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Inhibikase raises ~$10M via registered direct offering and private placement with warrants","bullets":["Offering includes 6,744,187 shares/equivalents at $0.86/share in registered direct, plus 4,883,721 in private placement.","Issued unregistered warrants to purchase up to 11,627,908 shares at $0.75/share, exercisable for 5 years.","Gross proceeds ~$10M; net proceeds for clinical trials, product development, and working capital.","Terminated prior at-the-market equity distribution agreement with Piper Sandler (no sales made).","H.C. Wainwright acted as exclusive placement agent; offering expected to close January 27, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-016224","json":"https://secwatch.observer/filing/0001193125-23-016224.json","markdown":"https://secwatch.observer/filing/0001193125-23-016224.md","text":"https://secwatch.observer/filing/0001193125-23-016224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/d369483d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T08:21:46.838136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21146782e224e43e48ada7d627a18b2133cfcd73","claim":"Inhibikase Therapeutics, Inc. entered into PIPE Purchase Agreement with the same institutional investor (effective 2023-01-25).","evidence_excerpt":"The Company also entered into a securities purchase agreement (the “PIPE Purchase Agreement” and, together with the Registered Direct Purchase Agreement, the “Purchase Agreements”) and a registration rights agreement (the “Registration Rights Agreement”) in connection with a concurrent private placement (the “PIPE Private Placement”) with the same institutional investor (the “PIPE Purchaser” and, together with the Registered Direct Purchaser, the “Purchaser”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the same institutional investor"},{"label":"Effective","value":"2023-01-25"}],"fact_type":"material_agreement"},{"claim_id":"4eac688972e3968c461023f02b2cabef40a5793c","claim":"Inhibikase Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.","evidence_excerpt":"H.C. Wainwright & Co., LLC (“Wainwright”) acted as the exclusive placement agent for the Offerings. The Company entered into an engagement letter (“Engagement Letter”) with Wainwright for potential financings.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"}],"fact_type":"material_agreement"},{"claim_id":"5aa8dd022605b751c2b2e4d1ca2e45bf38acbef9","claim":"Inhibikase Therapeutics, Inc. entered into Registered Direct Purchase Agreement with an institutional investor (effective 2023-01-25).","evidence_excerpt":"On January 25, 2023, Inhibikase Therapeutics, Inc. (“Company”) entered into a securities purchase agreement (the “Registered Direct Purchase Agreement”) in connection with a registered direct offering (the “Registered Direct Offering”) and concurrent private placement with an institutional investor (the “Registered Direct Purchaser”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523016224/0001193125-23-016224-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Effective","value":"2023-01-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}